Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for March 2008
March 3, 2008
- Alexza's AZ-104 (Staccato Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
- Pro-Pharmaceuticals Davanat Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
- Renovo Announces Results of Latest Phase 2 Studies of Juvista (Human Recombinant TGFbeta3)
- Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
- GTx Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
- HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
- LifeCycle Pharma Announces Positive Top-line Results of Phase II Clinical Trial of LCP-Tacro for the Prevention of Organ Rejection after Kidney Transplantation
- Array BioPharma Announces Positive Phase 2 Top-Line Results in Inflammatory Pain Clinical Trial
- PhytoMedical's Latest Anti-Cancer Compounds Kill Human Colon Cancer Cells
- Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
March 4, 2008
- Inovio Biomedical to Present New Data from Melanoma Immunotherapy Clinical Trial at DNA Vaccines Forum 2008
- Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Women's Cancer
- Sirtris Pharmaceuticals' SRT501 Slows Retinal Ganglion Cell Loss During Optic Neuritis in a Preclinical Model of Multiple Sclerosis
- Advaxis Scientists Publish Research of Listeria Monocytogenes-Based Vaccine for Prostate Cancer in Latest Edition of Cancer Immunology & Immunotherapy
- Lifetime Probability of Needing a Stem Cell Transplant is Much Higher Than Previously Reported, Data Shows
- International symposium reports on the use of antivirals in patients with H5N1
- Panacos Announces Discovery of Bevirimat Patient Response Predictors
- UCB: Early Data on Cimzia from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
March 5, 2008
- Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
- CHOP-Zevalin Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
- Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
March 6, 2008
- PharmAthene Completes Pharmacokinetic Studies of Protexia; Program on Target for IND Filing in 2008
- Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities
- High Levels of Estrogen Associated with Breast Cancer Recurrence
- ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
March 7, 2008
- Alcon Presents Clinical Trial Data on Anecortave Acetate for Glaucoma
- Juvista Phase II Trial Results in Scar Revision and Breast Augmentation Surgery
- Repros' Proellex Safety Data Presented At The 13th World Congress of Gynecological Endocrinology
- THE LANCET Publishes Phase IIa Study Results with Cytos Biotechnology’s Hypertension Vaccine CYT006-AngQb
- SPMSD release: Gardasil
- Experts Available to Discuss Study Showing Link Between High Levels of Estrogen and Breast Cancer Recurrence
March 10, 2008
- Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
- Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
- Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
- Sirtris Pharmaceuticals Collaborator Presents Neuroprotective Data for Oral Drug Candidate SRT501 at North American Neuro-Ophthalmology Society Meeting
- Genzyme Announces Presentation of New Positive Data on Carticel
- GSK Cervical Cancer Candidate Vaccine Cervarix Demonstrates Long-Term Protection for More Than Six Years
- Anavex 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Preclinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing no Measurable Activity
- Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
- Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
- Clinical Data on Lenocta, a Protein Tyrosine Phosphatase Inhibitor in Development at VioQuest Pharmaceuticals, Accepted for Oral Presentation at ASCO
- Potential Brain Cancer Drug for Children May Damage Bones
- Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
March 11, 2008
- I-Flow Leads Infection Prevention Trend by Using Silver with Antimicrobial Properties in Medical Devices
- Femara helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
- Genitope Corporation to Suspend Development of MyVax Personalized Immunotherapy
- Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
- Inovio Biomedical's Electroporation Delivery Technology Demonstrates Safety and Positive Clinical Responses with Melanoma DNA Immunotherapy
- Peregrine Pharmaceuticals Announces Positive Data From Cotara Brain Cancer Trials
- Oculus Innovative Sciences to Announce Additional Phase II Data and Data from Two Recent International Studies at DFCon 08
- Nymox Releases Further Results from Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia
- Oxogeme Reports Positive Primate Ocular Tolerance and Penetration Data with Topical Formulation of Zybrestat for Ophthalmology
- Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
- Nymox Releases Further Results from Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia
March 12, 2008
- Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of Intravenous Methylnaltrexone for Postoperative Ileus
- Avexa Reports Superior Results in ATC Phase IIb Clinical Trial Update
- Urigen Announces Positive Phase II Clinical Trial Results with URG101
- XenoPort Announces Positive Results of a Phase 1 Clinical Trial of XP21279
- Unigene Successfully Completes Phase I/II Clinical Study for Oral Calcitonin
- JAMA Article Provides False Support for CDC's Do-Nothing Position on MRSA
- CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results in Psoriasis
- OctoPlus Announces Publication of Phase I Locteron Results in the Journal of Interferon and Cytokine Research
March 13, 2008
- Publication of Clinical Results Underscores Velcade (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
- Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera for Gaucher Disease
- Cambria Biosciences' Chemical Genetics Platform is Featured in Nature Article Describing a New Pharmaceutical Mode of Action
- MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
- Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis
- Researchers Find Cause of Severe Allergic Reaction to Cancer Drug
- Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
- Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
March 14, 2008
- Inspire Announces Poster Presentations at 2008 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
- Oculus Innovative Sciences Announces Additional Phase II Data for Microcyn Technology in Mildly Infected Diabetic Foot Ulcers
- The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Greer Reports Favorable Results of Phase IIb Clinical Trial of Short Ragweed Sublingual-Oral Immunotherapy at American Academy of Allergy Asthma and Immunology Annual Meeting
- Modified Virus Vaccine Shows Promise in Mouse Model of Breast Cancer
March 17, 2008
- Akesis Pharmaceuticals Provides Preliminary Data from Phase IIa Trial of AKP-020 for Type 2 Diabetes
- Sepracor Presents Safety Data on Omnaris AQ and Omnaris HFA Nasal Sprays at American Academy of Allergy Asthma and Immunology (AAAAI)
- Baxter Presents Latest Clinical Trial Results of Gammagard Liquid Administered Subcutaneously
- Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
- Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
- Medivation's Dimebon Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
- Valeant Pharmaceuticals Reports Encouraging Phase IIb Results at Treatment Week 12 for Taribavirin
- New Data Show Advair Reduces Asthma-Related Hospitalization and Emergency Department Visits
- Fludarabine, Mitoxantrone and Zevalin Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
- New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
- Hepatitis C Virus DNA Vaccine Shows Safety When Delivered by Inovio Biomedical's Electroporation Delivery System in Phase I/II Clinical Study at Karolinska University Hospital
- GSK Data Suggests Efficacy of Advair and Serevent is Not Impacted by Genetic Profile
- Greer's Sublingual-Oral Immunotherapy Clinical Trials Supporting the Safety of Home-Administered Treatment Published in the Annals of Allergy, Asthma and Immunology
- Study Analyzed Long-Term Symbicort Use in Children With Persistent Asthma
- New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases
- Study Shows Privigen 10% Liquid Immunoglobulin Preparation for Intravenous Use, Is an Effective Replacement Therapy in Patients with Primary Immune Deficiencies
- NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
- Oculus Innovative Sciences Announces Positive Results From Three Abstracts Evaluating the Use of Microcyn Technology in Diabetic Foot Ulcers
- Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to Reolysin During a Phase I Clinical Trial
- Scientists Identify New Leads for Treating Parasitic Worm Disease
- MediGene Achieves Excellent Efficacy Data of EndoTAG-1 in Clinical Phase II Trial in Pancreatic Carcinoma
- Nuvelo Announces Phase 2 Sonoma-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
March 18, 2008
- VioQuest Pharmaceuticals Announces Presentations at Annual Meeting of the American Association for Cancer Research
- Hollis-Eden Pharmaceuticals Reports Positive Preliminary Data from Ongoing Phase I/II Clinical Trial with Triolex in Obese Insulin Resistant Subjects
- Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
- iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
- NPS Reports Successful Gattex Extension Study
- Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
- CeraShield Coated Endotracheal Tubes Provide up to 21 Days of Protection against Bacterial Colonization in Preclinical Testing
- NovaBay Pharmaceuticals (NBY) Publishes on the Design of New Class of Antimicrobial Compounds It Named Aganocides
- BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept
- Study Compares Bronchodilatory Effects of Symbicort and Advair in Adults With Asthma
- C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
- Lipid Sciences' HDL Mimetic Peptide Demonstrates Significant Anti-Atherosclerosis Effect in a Key Animal Model
- Data Presented at International Psoriasis Meeting Support Potential New Role for Biologic Treatment Etanercept in Management of Childhood Psoriasis
- Leading Rheumatologists Agree Clinical Remission a Key Goal in Rheumatoid Arthritis
- 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter
- Lev Presents Results of Phase III Study Supporting Safety and Efficacy of Cinryze (C1 inhibitor) as Prophylactic Therapy for HAE
- Orexo's Product NLA Nasal Spray Shows Excellent Local Tolerability in Patients with Rhinitis
- Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
March 19, 2008
- Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment
- Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
- Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
- X-ray Images from Liver Phase I Trial Presented at Society for Interventional Radiology 33rd Annual Scientific Meeting
March 20, 2008
- EPIX Pharmaceuticals Announces Discontinuation of PRX-00023 Clinical Development Program
- Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
- Adherex to Present ADH-1 Phase I/II Melanoma Trial Data at the 2008 Annual Meeting of the American Society Of Clinical Oncology (ASCO)
- ZIOPHARM Presents Promising Early Data from Phase Ib Study of Indibulin at 6th International Symposium on Targeted Anticancer Therapies
- RXi Pharmaceuticals to Present Data on the Cellular Mechanism of RNAi Interference at Keystone Symposia's RNAi, MicroRNA, and Non-Coding RNA Meeting
- NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
March 21, 2008
- Antigenics to Present Phase 3 Oncophage (vitespen) Data in Kidney Cancer at European Association of Urology Annual Congress
- Perioperative Eloxatin-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
- Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
- International Actemra Rheumatoid Arthritis Study Highlighted in The Lancet
- Novel drug Actemra significantly improves the debilitating symptoms of Rheumatoid Arthritis in patients who have an inadequate response to standard therapy
March 24, 2008
- MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
- Spectrum Pharmaceuticals Presents Data on SPI-1620, a Novel Adjunct to Cancer Therapy, at the 6th International Symposium on Targeted Anticancer Therapies
- Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of 'Knock-Out' Cell Lines
- Baraclude (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
- Accentia Biopharmaceuticals to Announce Top-Line SinuNase Phase 3 Clinical Trial Results Later Today
- AVAX to Present Results of Phase I-II Study of MVax at 2008 Meeting of the American Society of Clinical Oncology (ASCO)
- Revised: Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
March 25, 2008
- Oxford Biomedica Report Encouraging New Phase II Trial Results with Trovax in Prostate Cancer
- Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
- Chelsea Therapeutics Reports Significant Efficacy of CH-4051 in Reduction of Collagen-Induced Arthritis in Animal Model
- Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
- EPIX Pharmaceuticals to Present Phase 2a Alzheimer's Data at Keystone Symposia
- Circulation Publishes Data Showing Kynapid (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
- Researchers Report Neublastin Virtually Restores Complete Long-term Sensory Motor Function in Preclinical Studies
- ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans
- Nastech Pharmaceutical Company Inc. to Present RNAi Data
- Yale and Asuragen Scientists Show That a microRNA Can Reduce Lung Cancer Growth
- Strong Trend of Effectiveness Indicated in Lipid Sciences' First in Man Clinical Trial of HDL Selective Delipidation
March 26, 2008
- Cancer Researchers at Manhattan-based St. Vincent's Comprehensive Cancer Center Discover Genes That Can Determine How Patients Respond to Pre-Leukemia Drug
- Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
- Cerus Announces Major Presence at Upcoming International Society of Blood Transfusion Conference
- Levitra Therapy Suitable for Men With High Cholesterol
- Eric J. Topol, M.D., to Present Late-Breaking Lecture About Advancements in Genomics of Cardiovascular Disease at ACC's 57th Annual Scientific Session
- Cerus Announces Major Presence at Upcoming International Society of Blood Transfusion Conference
- Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
- CytRx to Present Stroke Recovery Data at the Sixth International Workshop on The Molecular Biology of Stress Responses
- Best Practice Database: Complimentary Excerpt of Scientific Publications Strategy Study
- Nature Publishes Study by Santaris Pharma Scientists and Collaborators: LNA-mediated microRNA Silencing in Non-human Primates
March 27, 2008
- ImmuneRegen BioSciences Releases Study Results Showing Homspera Stimulates Adult Stem Cell Activity
- Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
- Vertex Announces Positive Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis
- Vertex Announces Positive Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cys
- SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
- Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
- Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease
- Orexo Announces Results Confirming the Clinical Profile of OX17 In Reflux Disease (GERD)
- Kaiser Permanente Study Shows That a Larger Abdomen in Midlife Increases Risk of Dementia
- New data presented at European Association of Urology (EAU) Congress in Milan
- Genfit Shows Encouraging Results in GFT505 First Clinical Trial of Efficacy
- IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
- RxGen and Santaris Pharma Use LNA-antimiR Technology to antagonize the liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol
March 28, 2008
- Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity during the Performance of Cognitive Tasks
- Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
- Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
- LDL Particle Measurement by NMR Recognized in Consensus Statement by the American Diabetes Association and the American College of Cardiology
- Sirtris Pharmaceuticals Scientific Advisor Shows SIRT1 Activation Improves Huntington's Disease In Preclinical Model
- Positive Results from Visudyne Combination Therapy Study Reported at Annual Macula Society Conference
- VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
March 31, 2008
- UCB (BE) - Phase II results for CDP791 in non-small cell lung cancer support further clinical development
- Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
- Crestor Outcomes Study Jupiter Closes Early Due To Unequivocal Evidence Of Benefit
- Update on Achieve: A Study of Merck's Investigational Extended-Release Niacin/Laropiprant (Cordaptive)
- 12-Month Data From Endeavor IV Show Strong Clinical Efficacy of Medtronic's Drug-Eluting Stent Across All Patient Groups
- Merck/Schering-Plough Pharmaceuticals Comments on Results of the Enhance Study
- ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
- Vertex Pharmaceuticals Announces Acceptance of Late-Breaker Abstract on Telaprevir
- Gamma Secretase Modulators Show Promise in Alzheimer's Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
- Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
- BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
- Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
- Abbott's XIENCE V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
- Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy (PML) Programs at RNAi Keystone Symposium
- Drug-Eluting Stents Outperform Bare Stents in Heart Attack
- Endeavor Stent Safety Profile Affirmed in Long-Term Experience
- Delcath Systems Presents Positive Phase II Data on Delcath PHP System in Treatment of Inoperable Liver Metastases
- Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
- MIV Preliminary Nine-Month Human Data Affirms Excellent Safety and Efficacy of VESTAsync Polymer-Free Drug-Eluting Stent
- Novelos Therapeutics Announces Continued Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Harvard Cancer Center
- Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
- Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
- Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
- SPIRIT II Explores Long-Term Performance of XIENCE V Stent
- Abbott's Phase III Studies of Investigational TriLipix (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
- Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis Platform in HIV at Keystone Symposia
- Landmark OnTarget Trial Demonstrates Micardis is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
- King Pharmaceuticals Presents Positive Results of CorVue Phase III Clinical Trials at the American College of Cardiology (ACC) Annual Scientific Conference
- Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (Cordaptive) Reported Significantly Less Flushing Than Patients Treated with Niaspan in Phase III Study
- New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
- Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
- Repros Reports Interim Safety Results From Ongoing One-Year Open Label Study of Proellex(R) in the Treatment of Uterine Fibroids
